11/14/2025 Formosa Pharmaceuticals, Inc. spent a meaningful day today at the shoreline of Tamsui, New Taipei City, where our team members joined forces to clean up the coast and protect our precious marine environment. This beach clean-up initiative is a core component of our ongoing commitment to ESG (Environmental, Social, and Governance) and environmental sustainability. …
10/08/2025 Formosa Pharmaceuticals announced its participation in the inaugural advocacy conference of the “Vision-Friendly Alliance,” initiated by Dialogue in the Dark (DiD) Social Enterprise, held on the eve of World Sight Day (October 8). Joining hands with partners across industry, government, academia, and social welfare, the company aims to advance a more inclusive and accessible …
ESG in Action: Formosa Pharmaceuticals Backs the Alliance’s Five Key Actions Read More »
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals NASHVILLE, Tenn. and Taipei, Taiwan, June 9, 2025 – Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for …
Formosa Pharmaceuticals and Adalvo Limited Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain TAIPEI – May 28, 2025 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW) announced that the company has entered into an exclusive licensing agreement with Adalvo Limited (“Adalvo”) in the European and Brazilian markets for exclusive …
Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico TAIPEI – May 07, 2025 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. (“Apotex”), for exclusive rights in Mexico …
Formosa Pharmaceuticals and Almac Discovery Announce Licensing Agreement for ALM-401, a First-in-Class Bispecific ADC targeting EGFR/ROR1 for the Treatment of Solid Tumors TAIPEI – May 6th, 2025 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW) announced that the company has entered into an exclusive licensing agreement with Almac Discovery, a Northern Ireland-based research driven drug discovery company, …
Formosa Pharmaceuticals and Saval Corporation Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain TAIPEI – April 26, 2025 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW) announced that the company has entered into an exclusive licensing agreement with Laboratorios Saval (“Saval”), a Chilean-based pharmaceutical company operating in Central and …
Cipla and Formosa sign multi-regional licensing deal for Clobetasol Suspension This partnership aims to enhance ophthalmic care by providing better treatment for post-operative inflammation and pain in patients across 11 countries. TAIPEI/INDIA – March 17, 2025 – Taiwan-based Formosa Pharmaceuticals (6838.TW) today announced an exclusive licensing agreement with Cipla Limited (BSE: 500087; NSE: CIPLA EQ) …
Formosa Pharmaceuticals and Medvisis Switzerland Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain TAIPEI – November 28, 2024 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW) announced that the company has entered into an exclusive licensing agreement with Medvisis Switzerland AG (“Medvisis”) in Switzerland and Liechtenstein, for exclusive rights …
Formosa Pharmaceuticals Announces Successful Top-Line Results from CPN-303, a Phase 3 Trial in Chinese Subjects for the Treatment of Inflammation and Pain after Cataract Surgery TAIPEI – November 4, 2024 – Formosa Pharmaceuticals, Inc. (6838.TW) reports completion and successful top-line results from CPN-303, a Phase 3 clinical study of APP13007 (GPN00833), conducted in Chinese cataract …